Bring the immune system one step Ahead of cancer

An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology

0 %

of patients currently undergoing
treatment for solid tumors will experience treatment failure.

Our mission at Brenus is to fight relapsing diseases in cold solid tumors, which is currently the biggest unmet need in oncology.

Cancer =
A moving target

The efficacy of current approaches is compromised by no anticipating tumor plasticity and resistances mechanisms and must be combined to be efficient.

Brenus Pharma’s solution educates patients’ immune system to anticipate and avoid their cancer relapse

Represent heterogeneity of the targeted indication

Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.

Increase antigenicity

Our STC manufacturing overpasses current approaches by covering a broad & higher-quality range of tumor antigens.

Increase immunogenicity

Haptenization process is a proven immunogenic tagging** sustainably boosting antigen’s immune recognition. It’s safely ensure immune system activation.

STC 1010

Lead candidate

targeting a huge unmet need and adressing solution for colorectal cancer patients

STC Platform

Innovative relay of technology

mimicking patient’s relapsing condition and generating first-in-class immunotherapy with limitless potential


Founder & President
Founder & Chief Scientific Officer
Chief Executive Officer
Lead Technical Operations
Senior Lead Medical Affairs
Lead Strategic Marketing & External Opportunities
Communication Manager
Scientific Project Manager
Head of Scientific Board Pr of Oncology
Pr of Immunology
Pr. of Medical Oncology

See why engaging with us will bring about a change of paradigm.

With the support of

Our awards


Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens


Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets